Organization · Corporate Venture Capital
Dose of Venture
Astellas Venture Management (AVM) is the corporate venture capital arm of Astellas Pharma, focusing on early-stage biotechnology investments in therapeutics and platform technologies. Based in South San Francisco, AVM aims to enhance Astellas' R&D pipeline through strategic equity investments.
Overview
What Dose of Venture does
What Dose of Venture is
Astellas Venture Management (AVM) is the corporate venture capital arm of Astellas Pharma, focusing on early-stage biotechnology investments in therapeutics and platform technologies. Based in South San Francisco, AVM aims to enhance Astellas' R&D pipeline through strategic equity investments.
How it participates in the startup ecosystem
The current public profile supports funder capabilities. Each capability below is shown separately so organization identity and role-specific information do not get conflated.
Operational profile
Organization status and context
Organization status describes the entity itself. Funding and program availability appear within the relevant capability profile.
- Operational status
- Active
- Organization type
- Corporate Venture Capital
- Founded
- Founded in 2001
- Approximate age
- About 25 years
- Structured capabilities
- Funder
- Last reviewed
- May 3, 2026
Official channels
Find Dose of Venture elsewhere
Open the official website or a supported primary organization account.
Capability profile
Dose of Venture as a funder
Investment thesis
Astellas Venture Management (AVM) supports pre-clinical, cutting-edge science that can bring value to patients by investing in early-stage biotechnology companies developing therapeutic programs and platform technologies.
Focus narrative
AVM invests in privately owned early-stage biotechnology companies that are developing therapeutic programs and platform technologies for drug discovery and development. The organization prioritizes investments in innovative therapeutic approaches that align with Astellas Pharma's research and development strategy, particularly those addressing unmet medical needs.
Value beyond capital
AVM acts as a liaison between portfolio companies and Astellas Pharma, facilitating future collaborations, licensing, or acquisitions. This strategic positioning enhances the value of investments by aligning them with Astellas' R&D efforts.
Focus and fit
- Stages
- Pre-seed · Seed · Seed+
- Regions
- North America · Global
Availability
- Currently deploying
- Yes
Portfolio and track record
- Recorded portfolio count
- 104
Portfolio context
Solu Therapeutics: Developing STX-0712 for CMML and advanced hematologic malignancies (Series A April 2025). Syntax Bio: Focused on drug discovery. PhoreMost: Specializes in drug discovery platform technology. DeepSeq.AI: Winner of the 2025 Astellas Future Innovator Prize, likely involved in AI for genomic sequencing. Serna Bio: Winner of the 2025 Astellas Future Innovator Prize, likely focused on RNA therapeutics.
Common questions
What to know about Dose of Venture
Upseed classifies Dose of Venture under the Corporate Venture Capital organization type. Its current public profile includes funder capabilities.
Source and update disclosure
Know what this page is based on
Source basis
Public organization and program material, official websites, and structured Upseed records.
Last reviewed
May 3, 2026
Known limits
Capability profiles appear only when a structured public profile also contains decision-useful role evidence. Terms and availability can change.
Upseed is an independent guide. It is not affiliated with or endorsed by the organization described on this page.